Skip to main content

Inbrija

Generic name: levodopa inhalation capsulesLEE-voe-DOE-pa ]
Dosage form: inhalation capsule (42 mg)
Drug class: Dopaminergic antiparkinsonism agents

Medically reviewed by Philip Thornton, DipPharm. Last updated on Mar 21, 2024.

What is Inbrija?

Inbrija is an inhaled prescription medicine used to treat symptoms of Parkinson's disease that come back (OFF episodes) while you are taking another medicine called carbidopa and levodopa.

Inbrija is not to be used in place of any medicine you take daily for Parkinson's disease.

It is not known if Inbrija is safe or effective in children.

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Before taking this medicine

Do not use Inbrija if you have used an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others.

To make sure Inbrija is safe for you, tell your doctor if you have:

It is not known whether Inbrija inhalation will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.

How should I use Inbrija?

Use Inbrija exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.

Inbrija is for use only in people who are currently taking carbidopa and levodopa. Do not stop taking your daily Parkinson's medications or change your dosing schedule without your doctor's advice.

For best results, use Inbrija when an "off episode" begins (when your Parkinson's symptoms start to return). Do not use Inbrija more than 5 times per day.

Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you do not understand these instructions.

Inbrija is a powder that comes with a special inhaler device and blister packs containing capsules of the medicine. You will load 2 capsules (one at a time) into the inhaler device each time you use the medicine. Pushing the handle of the device onto the mouthpiece will pierce the capsule and release the medicine into the inhaler.

Do not swallow a Inbrija capsule. It is for use only in the Inbrija inhaler device.

This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using Inbrija.

Do not stop using Inbrija suddenly after long-term regular use, or you could have unpleasant withdrawal symptoms (fever, confusion, muscle stiffness, changes in breathing and heart rate). Ask your doctor how to safely stop using this medicine.

Store at room temperature away from moisture and heat. Keep each capsule in the blister pack until you ready to load the inhaler device. Do not store capsules inside the device.

Throw away the device when your capsules run out. Always use the inhaler device that comes with each new prescription.

Dosing information

Usual Adult Dose for Parkinson's Disease:

84 mg via oral inhalation as needed when OFF period starts to return; may dose up to 5 times a day
Maximum dose per OFF period: 84 mg
Maximum daily dose: 420 mg

Comments:
-Therapy should be taken when symptoms of an OFF period start to return.
-This drug has shown efficacy only in combination with levodopa/carbidopa therapy.
-Oral inhalation capsules should only be used with the Inbrija(R) inhaler; capsules should not be swallowed whole as the intended effect will not be obtained.

Use: For the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.

What happens if I miss a dose?

Since Inbrija is used when needed, you may not be on a dosing schedule. Skip any missed dose if it's almost time for your next dose. Do not use two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include muscle pain or weakness, fever, dark colored urine, little or no urination, fast heartbeats, or fainting.

What should I avoid while using Inbrija?

Avoid driving or hazardous activity until you know how Inbrija will affect you. Dizziness or drowsiness can cause falls, accidents, or severe injuries.

Inbrija side effects

Get emergency medical help if you have signs of an allergic reaction to Inbrija: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using Inbrija and call your doctor or seek emergency medical attention if you have a wheezing, chest tightness, or trouble breathing after inhaling this medicine.

Call your doctor at once if you have:

Some people using this medicine have fallen asleep during normal daytime activities such as working, talking, eating, or driving. This side effect has occurred up to 1 year after the start of treatment with Inbrija. Tell your doctor if you have any problems with daytime drowsiness.

Common Inbrija side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Inbrija?

Using Inbrija with other drugs that make you drowsy can worsen this effect. Ask your doctor before using opioid medication, a sleeping pill, a muscle relaxer, or medicine for anxiety or seizures.

Tell your doctor about all your other medicines, especially:

This list is not complete. Other drugs may interact with levodopa, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Popular FAQ

The out-of-pocket cash price for Inbrija (levodopa inhalation) 42 mg inhalation capsules is about $1,295 for a supply of 60 capsules, but most people do not pay this price. If you have commercial insurance and Inbrija is covered on your plan, you may be eligible to receive it for as little as $30 per month. Continue reading

The short-acting (immediate-release) formulation of carbidopa/levodopa takes effect within about 20 to 50 minutes. The long-acting (extended-release) formulation starts to work closer to the 50-minute timeframe. Continue reading

The immediate-release (short-acting) form of carbidopa/levodopa is usually taken 3 or 4 times each day, while the extended-release (long-acting) form is typically taken 2 to 4 times each day. Continue reading

Carbidopa/levodopa is unlikely to cause high blood pressure (hypertension). It was reported in less than 1% of patients in clinical trials and is not considered a common adverse reaction related to the drug. Continue reading

Levodopa is a central nervous system agent that helps people with Parkinson’s because it is converted into dopamine in the brain. It helps to alleviate the symptoms of the disease by providing a supply of dopamine, which is lacking in people with Parkinson's.

Levodopa works best to help treat the slowness and stiffness or rigidity associated with Parkinson’s disease, and in some cases may treat the tremor as well. It does not slow or reduce the progression of Parkinson’s disease. Continue reading

The recommended time to take Ongentys (opicapone) is once daily at bedtime and at least one hour after food. Eating is also not recommended for an hour of taking Ongentys.

By taking Ongentys at night or at least one hour apart from levodopa, the amount of levodopa available after a dose is increased, but any interaction between the two drugs during the levodopa absorption phase is avoided. Taking Ongentys at night means that there’s greater flexibility to adjust when levodopa is taken during the day, without the need to consider potential absorption interactions. Continue reading

More FAQ

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Inbrija only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.